Evaluating immune-related adverse events (irAEs) in a real-world cohort with lung cancer receiving immunotherapy

被引：0
|
作者：
Hu, Xiao [1 ]
Pan, Stacey [1 ]
Salei, Yana V. [2 ]
Lin, Jeffrey H. [2 ]
Parsons, Susan K. [1 ,3 ]
机构：
[1] Tufts Med Ctr, Div Hematol Oncol, Dept Med, Boston, MA USA
[2] Tufts Med Ctr, Dept Med, Boston, MA USA
[3] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PP01.67
引用
收藏
页码：E32 / E32
页数：1
相关论文
共 50 条
  • [41] Validation of Immune-Related Adverse Event (irAE) Case Definitions in a Real-World Lung Cancer Population
    Heyward, James S.
    Segal, Jodi B.
    Mehta, Hemalkumar B.
    Murray, Joseph C.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2025, 34 (02)
  • [42] Role of Immune-Related Adverse Events (irAEs) and Albumin in Non-Small-Cell Lung Cancer (NSCLC)
    Bawek, S.
    Kalvapudi, S.
    Vedire, Y.
    Pachimatla, A.
    Jain, P.
    Yendamuri, S.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S612 - S613
  • [43] Association of efficacy of anti-PD-1 immunotherapy in patients with advanced cancer with immune-related adverse events (irAEs)
    Rogado Revuelta, Jacobo
    Romero-Laorden, Nuria
    Sanchez Torres, Jose Miguel
    Pacheco-Barcia, Vilma
    Ballesteros, Anabel
    Maria Ramos-Levi, Ana
    Arranz, Reyes
    Lorenzo, Alicia
    Gullon, Pedro
    Garrido Garcia, Ana
    Maria Serra, Jose
    Donnay, Olga
    Adrados, Magdalena
    Costas, Pablo
    Aspa, Javier
    Alfranca, Arantza
    Fenor De la Maza, Maria Dolores
    Mondejar, Rebeca
    Colomer, Ramon
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [44] Review: The role of IL-6 in immunotherapy of non-small cell lung cancer (NSCLC) with immune-related adverse events (irAEs)
    Ke, Wanhai
    Zhang, Li
    Dai, Yan
    THORACIC CANCER, 2020, 11 (04) : 835 - 839
  • [45] Immune-Related Adverse Events (irAEs) in Cancer, with Inputs from a Nursing Expert: A Review
    Buch, Sajad Ahmad
    Baba, Mudasir Rashid
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2022, 43 (02) : 144 - 152
  • [46] Proactively Improving the Management of Immune-Related Adverse Events (irAEs) in a Community Cancer Program
    Dobrea, L.
    Nguyen, E. Esposito
    Maurice, J.
    Carandang, M.
    Boyd, D.
    Haimowitz, S.
    Gracie-King, L.
    Kim, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1065 - S1065
  • [47] Immune-Related Adverse Events (irAEs): Implications for Immune Checkpoint Inhibitor Therapy
    Zhou, Nanruoyi
    Velez, Maria A.
    Owen, Dwight
    Lisberg, Aaron E.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (09): : 1287 - 1290
  • [48] Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responses
    Blum, Steven M.
    Rouhani, Sherin J.
    Sullivan, Ryan J.
    IMMUNOLOGICAL REVIEWS, 2023, 318 (01) : 167 - 178
  • [49] Immunotherapy - immune-related adverse events and their management
    Petrausch, Ulf
    THERAPEUTISCHE UMSCHAU, 2019, 76 (04) : 195 - 198
  • [50] Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
    Naidoo, Jarushka
    Murphy, Catherine
    Atkins, Michael B.
    Brahmer, Julie R.
    Champiat, Stephane
    Feltquate, David
    Krug, Lee M.
    Moslehi, Javid
    Pietanza, M. Catherine
    Riemer, Joanne
    Robert, Caroline
    Sharon, Elad
    Suarez-Almazor, Maria E.
    Suresh, Karthik
    Turner, Michelle
    Weber, Jeffrey
    Cappelli, Laura C.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (03)
12345